{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-011205","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.108832+00:00","generated_at":"2026-06-27T00:19:46.884585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024","bullets":["Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).","Cash and marketable securities $130.7M as of Dec 31, 2021; expected to fund operations into mid-2024.","R&D expenses rose to $4.1M in Q4 (vs $3.7M prior year) and $21.1M for full year (vs $12.0M).","Phase 1 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) has commenced after FDA IND clearance.","Jathin Bandari, M.D., appointed as Chief Medical Officer in January 2022; previously Interim CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-011205","json":"https://secwatch.observer/filing/0001213900-22-011205.json","markdown":"https://secwatch.observer/filing/0001213900-22-011205.md","text":"https://secwatch.observer/filing/0001213900-22-011205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/0001213900-22-011205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022011205/ea156484-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:19:46.884585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}